Frontier Capital Management’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-9,619
Closed -$5.39M 280
2020
Q4
$5.39M Buy
9,619
+3,219
+50% +$2.04M 0.04% 259
2020
Q3
$4.47M Sell
6,400
-28,328
-82% -$22.1M 0.04% 260
2020
Q2
$27.5M Buy
34,728
+20,899
+151% +$15.8M 0.24% 143
2020
Q1
$8.23M Buy
13,829
+2,739
+25% +$2.67M 0.09% 207
2019
Q4
$12.6M Buy
11,090
+7,729
+230% +$8.4M 0.09% 212
2019
Q3
$4M Sell
3,361
-4,930
-59% -$7.53M 0.03% 255
2019
Q2
$13.7M Sell
8,291
-3,070
-27% -$5.31M 0.1% 205
2019
Q1
$23.2M Sell
11,361
-165
-1% -$291K 0.16% 175
2018
Q4
$14.8M Buy
11,526
+6,198
+116% +$9.51M 0.12% 200
2018
Q3
$10.1M Sell
5,328
-1,994
-27% -$4.12M 0.06% 239
2018
Q2
$14.9M Buy
7,322
+3,348
+84% +$7.63M 0.11% 219
2018
Q1
$8.79M Sell
3,974
-3,522
-47% -$8.96M 0.06% 246
2017
Q4
$17.3M Sell
7,496
-4,423
-37% -$8.98M 0.13% 204
2017
Q3
$21.2M Buy
11,919
+6,473
+119% +$9.04M 0.15% 188
2017
Q2
$7.41M Buy
5,446
+1,031
+23% +$1.24M 0.05% 258
2017
Q1
$5.2M Sell
4,415
-11,137
-72% -$11.4M 0.04% 272
2016
Q4
$12.4M Buy
15,552
+7,446
+92% +$5.91M 0.1% 226
2016
Q3
$7.12M Buy
8,106
+3,389
+72% +$2.45M 0.06% 257
2016
Q2
$2.65M Sell
4,717
-2,439
-34% -$1.38M 0.02% 280
2016
Q1
$3.94M Sell
7,156
-4,170
-37% -$2.56M 0.03% 280
2015
Q4
$9.42M Buy
11,326
+10,295
+999% +$10.3M 0.08% 254
2015
Q3
$1.14M Sell
1,031
-671
-39% -$1.22M 0.01% 312
2015
Q2
$3.71M Sell
1,702
-17,603
-91% -$35.9M 0.03% 296
2015
Q1
$30.2M Sell
19,305
-17,554
-48% -$23.2M 0.22% 162
2014
Q4
$43.8M Buy
+36,859
New +$24.6M 0.32% 109

Other funds holding BLUE

Frontier Capital Management's BLUE Position: Q1 2021 in Review

Frontier Capital Management sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 9,619 shares — an estimated $5.39M sold.

Frontier Capital Management first reported a position in BLUE in Q4 2014 and held it in 25 quarters. The position peaked at $43.8M in Q4 2014. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.

  • Frontier Capital Management reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
  • Frontier Capital Management sold 9,619 bluebird bio shares in Q1 2021, an estimated $5.39M.
  • Frontier Capital Management first reported a position in bluebird bio in Q4 2014 and held it in 25 quarters.
  • Frontier Capital Management's bluebird bio position peaked at $43.8M in Q4 2014.
  • 229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.

Based on Frontier Capital Management's 13F filing for Q1 2021, filed 13 May 2021.